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Background
here are two general approaches to research
design for scientific study of intervention effectiveness:
the randomized controlled clinical trial (RCT) and the
observational study. (The term naturalistic study is not
used here, in an effort to distinguish the observational
study from a study of the natural history of an untreated
illness, which is often called a naturalistic study.)
Typically the RCT is preferred for a variety of reasons,
most importantly randomized treatment assignment.
However, there are some advantages of the observa-
tional study if it is appropriately analyzed. Here the dis-
tinction between the two designs, and advantages and
disadvantages of each for various settings, are consid-
ered. 
Randomized clinical trials
The primary goal in designing an RCT is to minimize the
bias in the estimate of the treatment effect.
1,2Three fun-
damental features of RCT design play a pivotal role in
minimizing bias: randomized treatment assignment, dou-
ble-blinded assessments, and a credible comparison
group. There are other essential goals in clinical trial
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Characteristics of randomized controlled clinical trials
(RCTs) and observational studies of psychiatric inter-
vention effectiveness are contrasted. Randomization
drives treatment assignment in an RCT, whereas clini-
cian and patient selection determine treatment in an
observational study. Strengths and weaknesses of ran-
domized and observational designs are considered. The
propensity adjustment, a statistical approach that
allows for intervention evaluation in a nonrandomized
observational study, is described here. The plausibility
of propensity adjustment assumptions must be carefully
evaluated. This data analytic strategy is illustrated with
the longitudinal observational data from the National
Institute of Mental Health Collaborative Depression
Study. Evaluations presented here examine acute and
maintenance antidepressant effectiveness and demon-
strate effectiveness of the higher categorical doses.    
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power to detect a clinically meaningful effect. An anti-
depressant trial, for example, must be designed to detect
an effect of about .40 standard deviation units (ie,
Cohen’s d=.40) and that requires about 100 participants
per treatment group for 80% statistical power for a t-test
with a two-tailed alpha-level of .05. However, there is a
tradeoff between power and feasibility. Recruitment of
100 per group is only feasible if compatible with both the
budget and the study site patient flow.
Furthermore, a trial must be designed such that the
false-positive rate (ie, Type I error) is acceptable; the
convention is 0.05. This is because false-positive treat-
ments, of course, do not reduce suffering in patients.
Finally, the design must be applicable. That is, the
recruited sample should yield results that generalize to
the target patient population; ie, that for which the indi-
cation is sought. 
A well-designed and well-implemented RCT is the gold
standard for treatment evaluation. This is because the
groups tend to be well-balanced at baseline, and therefore
subsequent group differences can be attributed to treat-
ment effects, providing strong internal validity. However,
there are limitations of results from RCTs for psychiatric
disorders. For example, trials for mood disorder interven-
tions typically involve short-term treatment (4 to 12
weeks) despite the chronic nature of the disorders.
Furthermore, the samples tend to be highly selected and
that restricts the generalizability (ie, external validity) of
the results. For instance, it has been shown that RCTs for
major depression evaluate treatment in rarefied samples,
excluding as many as 85% of those who are screened.
3
The exclusions are, for example, based on illness sever-
ity (too severe or not severe enough) and safety risk (eg,
suicidality, concomitant medication, or psychosis).
Therefore the results do not inform the treatment of
patients who have such features. Finally, the attrition
poses a serious threat to the internal validity of a clinical
trial. The attrition rates in antidepressant trials range from
30% to 40% and they are higher for antipsychotics, rang-
ing from 50% to 60%.
4 Self-selection of this type (ie, attri-
tion) and of this magnitude severely compromises ran-
domization. Features of design and analysis that reduce
the impact of attrition on RCTs of psychotropics have
been discussed in detail elsewhere.
1,2These include strict
adherence to the principle of intention to treat, in which
all randomized subjects are included in the primary analy-
ses,
5,6 use of mixed-effects models that include all available
data from participants, even those who terminate the
study prematurely,
7,8 and analyses of the sensitivity of
results to the assumptions of the analytic model.
Observational studies
In an observational study investigators observe, but do
not manipulate, the treatment that is received by partic-
ipants. Randomized treatment assignment is not used,
and this is the most fundamental difference between an
observational study and an RCT. In addition, placebo
controls and double-blinding of treating clinicians and
patients are not used in observational studies, though
blinded assessments could be administered. However,
RCTs and observational intervention study designs
share goals: minimizing bias, having sufficient statistical
power, controlling Type 1 error, and providing a feasible
design and widely generalizable results. The respective
emphasis of each goal varies across the designs. 
An observational study’s strength is typically applica-
bility, whereas it is more vulnerable to bias. A participant
in an observational study receives treatment based on
clinician and/or patient selection. That selection is very
likely based on illness severity at time of treatment
assignment. For example, those with more severe depres-
sion could much more likely receive an antidepressant
than those less depressed or asymptomatic. (An exam-
ple of this is provided below using data from the NIMH
Collaborative Depression Study.) Furthermore, at the
time a treatment decision is made it is quite possible that
illness severity will be related to outcome. In other
words, treatment assignment could be influenced by a
confounding variable or variables. As a consequence,
participants who are treated and those untreated are
rarely equivalent when treatment commences. 
The estimate of the treatment effect in observational
studies could very well be biased without proper statis-
tical adjustment. That is, the effect will not reflect the
results that would be seen if evaluated in several well-
conducted trials of the intervention. If only one variable
was responsible for treatment assignment, and that vari-
able was both known and collected, stratified analyses
could control the confounding effect. For instance, con-
sider the case where those with health insurance are
much more likely to receive an antidepressant interven-
tion (eg, pharmacotherapy, psychotherapy, or implanta-
tion device) than the uninsured. Separate analyses for
the insured and uninsured (ie, stratified analyses) would
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treatment effect was not dissimilar for the insured and
uninsured, the results could be aggregated or pooled.
However, it is unlikely that the treatment delivery mech-
anism is explained by just one variable. The focus of this
presentation is on a method to reduce bias in the obser-
vational estimate of the treatment effect in the presence
of multiple confounding variables.
Propensity score adjustment
The propensity score adjustment is used to estimate
causal treatment effects with nonequivalent comparison
groups and is readily applied to observational studies.
9
The adjustment is a balancing strategy. Its goal is to
decrease bias in the estimate of the treatment effect by
reducing treatment group imbalance. The propensity
score, e(x), represents the conditional probability of
receiving treatment, given, for example, pretreatment
clinical and demographic characteristics, such that
0≤e(x)≤1. The propensity score for each observation is
derived from a logistic regression model as described
below. Subjects with low propensity scores have charac-
teristics of someone unlikely to get treatment, whereas
those with high propensity scores have characteristics of
someone more likely to get treatment. 
Before the introduction of the concept of the propensity
score, Cochran
10 showed that analyses that are stratified
into quintiles of a confounding variable will remove
>90% of the associated bias. Building on these findings,
the propensity adjustment can be implemented through
stratification. The rationale for this is that within a
propensity score quintile (containing 20% of the obser-
vations), the variability in propensity scores will be
greatly reduced, albeit not necessarily a constant (as in
the health insurance example, above). Based on the con-
cept of restriction of range, propensity score stratifica-
tion will attenuate the association between the con-
founding variables and treatment. In addition to
stratification, matching, inverse probability weighting,
and covariate adjustment are other strategies to imple-
ment the propensity adjustment. Covariate adjustment,
though most commonly used, can be problematic.
9
Two stages of propensity analyses
The propensity adjustment is implemented in two stages:
(i) propensity score estimation, and (ii) treatment effec-
tiveness analyses. The first stage is the propensity model.
The propensity score is estimated based on parameter
estimates from a logistic regression model for cross-sec-
tional data or mixed-effects logistic regression model for
longitudinal data. A preponderance of the applications
and evaluations of the propensity methods have
involved cross-sectional data. However, evaluations of
the performance of propensity quintile stratification with
longitudinal observational data have supported its use
for bias reduction
11-15 and both examples presented
below involve longitudinal data. The dependent variable
in the propensity model is treatment (eg, novel vs stan-
dard) and the independent variables include demo-
graphic and clinical characteristics hypothesized to be
associated with treatment. 
The propensity adjustment assumes that treatment
assignment is strongly ignorable conditional on the
propensity score.
9The plausibility of this assumption can
be examined by evaluating the between-treatment group
balance on pretreatment variables (ie, the variables
included in the propensity score) after implementing the
propensity adjustment. For instance, this could be done
by comparing treatment groups on baseline variables
separately within each propensity quintile. Presumably,
the between-group effect size (eg, for baseline illness
severity) will be considerably smaller when the propen-
sity adjustment has been implemented, indicating
greater baseline between-treatment group balance. With
baseline balance, post-baseline groups differences on ill-
ness severity can more safely be attributed to the inter-
vention.
The second stage of implementing the propensity adjust-
ment involves treatment effectiveness analyses. As imple-
mented in the examples below, the observations are
stratified into quintiles of the propensity score. Unlike
unadjusted analyses, stratification involves separate
analyses for each propensity quintile. Effectiveness
analyses might be conducted with a t-test of severity rat-
ings or chi-square test of response rates for cross-sec-
tional data. For longitudinal data, in contrast, mixed-
effects linear regression, mixed-effects logistic
regression, or mixed-effects grouped time survival mod-
els, could be used. The choice among these analytic
approaches depends on the form of the dependent vari-
able. In each case, treatment is the primary independent
variable. The quintile-specific results can be pooled using
the Mantel-Haenszel procedure to provide one unified
estimate of the treatment effect. However, pooling can
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tile interaction has been evaluated and supported empir-
ically. As stated earlier matching, inverse probability
weighting, and covariate adjustment provide alternatives
to stratification. These alternatives are particularly use-
ful if the sample size precludes quintile stratification,
which, of course, involves only 20% of the observations
in each quintile-specific analysis.
Observational studies of 
antidepressant effectiveness
Two examples of observational evaluation of antidepres-
sants are presented below. Each includes two stages of
analyses: a propensity model and a treatment effectiveness
model. The former examines the magnitude and direction
of variables hypothesized to be associated with receiving
various ordered categorical antidepressant doses. The lat-
ter examines the antidepressant effect relative to a com-
parator, no antidepressant in these examples. Each exam-
ple comes from the National Institute of Mental Health
Collaborative Depression Study (CDS). The CDS is a lon-
gitudinal, observational study that recruited 955 subjects
from 1978 through 1981 who sought treatment for one of
the major mood disorders (major depressive disorder,
mania, or schizoaffective disorder) from one of five aca-
demic medical centers in the United States (Boston,
Massachusetts; Chicago, Illinois; Iowa City, Iowa; New
York, New York; and St Louis, Missouri). All subjects were
English-speaking, Caucasian, and at least 17 years of age.
Each subject provided informed written consent.
16 Each
example below included up to 20 years of follow-up data.
These data capture the repeated antidepressant exposure
a patient receives during the chronic course of depression:
episodes, recovery periods, and recurrences. 
Evaluation of acute antidepressant effects
The effectiveness of acute somatic antidepressant treat-
ments as administered in the community was exam-
ined.
17At intake into the CDS, each participant included
in the analyses met criteria for major depressive disor-
der had no history of mania, hypomania, or schizoaffec-
tive disorder and had no underlying minor or intermit-
tent depression of at least 2 years’ duration. The analyses
included 285 participants who recovered from their
intake episode and then had at least one recurrent affec-
tive episode over the course of the follow-up period. This
was done to accommodate the variables included in the
propensity model (as described below). The 285 partici-
pants had 3141 different antidepressant exposure inter-
vals over the course of time. Each of these intervals con-
stituted a unit of analysis, each with its own propensity
score—based strictly on variables assessed prior to the
start of the interval. Hence both treatment and propen-
sity for treatment were time-varying, as might be seen in
clinical practice.
Classification of antidepressant exposure
Participants were classified based on the ordinal cate-
gorical antidepressant dose they received during each
week of follow-up. Four ordered categorical antidepres-
sant doses ranged from no treatment to, for example,
≥300 mg imipramine or >30 mg fluoxetine. (Categorical
doses for 14 antidepressants are described in detail else-
where
17,18). A change from one antidepressant to another
did not initiate a new exposure interval, but instead
extended the current interval duration, unless the cate-
gorical dose was modified. Use of concomitant medica-
tions had no bearing on weekly exposure classification.
The unit of analysis in both examples presented here is
“antidepressant exposure interval,” which is defined as
a period of consecutive weeks during which the cate-
gorical antidepressant dose classification remained
unchanged. This is in contrast to most studies where the
unit of analysis is the participant per se. 
Propensity model
A mixed-effects ordinal logistic regression model exam-
ined the propensity for treatment intensity. Treatment
intensity was the ordinal-dependent variable, with four
ordered categorical antidepressant doses as described
earlier.
18,17 Demographic and clinical variables hypothe-
sized to be associated with treatment intensity were
included as independent variables in the propensity
model. The results indicate that those who had more
severe depressive symptoms, more prior episodes, and
more intensive somatic therapy in the past were signif-
icantly more likely to receive higher antidepressant
doses. This suggests that the prior course of illness was
more difficult for those who subsequently received
higher doses. Nevertheless, treatment comparisons could
be made by stratifying effectiveness analyses on the
propensity score because the propensity adjustment
Clinical research
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ciation between each propensity variable and antide-
pressant dose. 
Treatment effectiveness model
The effectiveness outcome involved survival intervals:
time from commencing a categorical antidepressant dose
until recovery (in weeks), as defined by Research
Diagnostic Criteria (RDC).
19 Each survival interval
ended in one of three ways: (i) recovery from depressive
episode; (ii) change in categorical antidepressant dose;
(iii) end of follow-up. The latter two were classified as
censored in the survival analyses, and censoring was
assumed to be unrelated to outcome. Each subject could
contribute multiple survival intervals to the analyses,
based on the number of distinct periods during which an
antidepressant dose remained constant over the course
of the 20-year follow-up.
Treatment effectiveness analyses were initially con-
ducted separately for each propensity score quintile. The
effectiveness of each of dose relative to no treatment
was tested using mixed-effects grouped-time survival
models.
20 The quintile-specific results were then pooled
because the propensity quintile by treatment interaction
was nonsignificant (-2LL=5.817, df=12, P=0.925). (An
interaction would have indicated that the treatment
effect varied across quintiles, in which case combining
results would be inappropriate.) The pooled results indi-
cate that, after controlling for propensity for treatment
intensity, those who received higher doses of antide-
pressant treatment were significantly more likely to
recover from a mood episode than those who received
no treatment (hazard ratio (HR): 1.86; 95% CI: 1.27-
2.72). In contrast, neither moderate doses (HR:1.13; 95%
CI:0.79-1.63) nor lower doses (HR: 0.86; 95% CI:0.55-
1.23) were associated with recovery. 
This observational study broadened the generalizability
of antidepressant RCT results. Unlike participants
enrolled in RCTs, the CDS sample included those tak-
ing concomitant medication, those with substance or
alcohol abuse, those with a history of serious suicide
attempts, and those with comorbid medical illnesses. In
summary, although more severely ill subjects were more
likely to commence antidepressant treatment with
higher doses, the propensity-adjusted analyses provided
an opportunity to demonstrate that those receiving
higher doses were more likely to recover.
Evaluation of maintenance 
antidepressant effects
Two hundred ninety-six CDS subjects were included in
this evaluation of antidepressants for the prevention of
recurrence of depressive episodes.
15 Among them they
had 1782 maintenance antidepressant exposure intervals
over 20 years of follow-up. 
Propensity for treatment
The propensity model was implemented with a mixed-
effects ordinal logistic regression model as described
above. The results indicate that those with more prior
episodes, those with more severe symptoms, those with
primary major depression at CDS intake, and those from
the New York, Iowa, and Chicago study sites were sig-
nificantly more likely to get more intensive maintenance
treatment, whereas younger subjects were significantly
less likely to get intensive treatment. These differences
among participants receiving various doses were
accounted for, once again, in effectiveness analyses that
were stratified by propensity score quintile. 
Using the stratification process, the association in the
ordinal logistic regression analysis between each of the
variables in the propensity score and antidepressant
dose was substantially attenuated. For example, the
association of study site with categorical dose was
reduced as follows (where Boston was the standard (ie,
OR=1.0): New York (OR=2.89; 95% CI: 1.45-5.74;
P=0.002 in unadjusted model vs OR=1.20; 95% CI:
0.72-1.98; P=0.490 in propensity adjusted model); St
Louis (OR=1.30; 95% CI: 0.79-2.13; P=0.302 vs
OR=.93; 95% CI: 0.62-1.40; P=0.717); Iowa (OR=2.61;
95% CI: 1.61-4.24; P<0.001 vs OR=1.35; 95% CI: 0.91-
1.99; P=0.138); Chicago (OR=2.49; 95% CI: 1.41-4.41;
P=0.002 vs OR=1.16; 95% CI: 0.76-1.77; P=0.484).
Similarly, the association of age with categorical dose
was reduced as follows (where ages 30 to 39 years was
the standard): <30 years (OR=0.51; 95% CI: 0.37-0.71;
P<0.001 in unadjusted model vs OR=0.99; 95% CI:
0.73-1.34; P=0.949 in propensity adjusted model); ages
40 to 49 (OR=1.11; 95% CI: 0.86-1.42; P=0.435 vs
OR=1.01; 95% CI: 0.80-1.29; P=0.913); ages 50 to 59
(OR=1.31; 95% CI: 0.90-1.90; P=0.156 vs OR=1.13;
95% CI: 0.83-1.54; P=0.450); ages 60+ (OR=1.34; 95%
CI: 0.87-2.07; P=0.188 vs OR=1.01; 95% CI: 0.74-1.36;
P=0.971). 
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The effectiveness analyses were conducted with a mixed-
effects grouped-time survival model to examine the time
until recurrence, which was defined as the number of
consecutive weeks during which the categorical antide-
pressant dose remained unchanged during a “well”
period (as defined by RDC
19). The quintile-specific treat-
ment effectiveness results were pooled because, once
again, the treatment by propensity interaction was not
statistically significant (-2LL=6:146; df=12; P=0.909). The
pooled results indicate that participants treated with
higher antidepressant doses were about half as likely to
experience a recurrence than those who received no
somatic treatment (odds ratio (OR): 0.50; 95% CI: 0.30–
0.84; Z=-2:60; P=0.009). In contrast, moderate doses were
associated with marginal protection (OR: 0.65; 95% CI:
0.41–1.01; Z=-1:92; P=0.055) and lower doses were not
associated with significant protection from recurrence
(OR: 0.98; 95% CI: 0.65–1.48; Z=-0.09; P=0.929). 
This observational evaluation of maintenance antide-
pressant treatment provides empirical evidence of the
effectiveness of higher categorical doses. As in the acute
treatment analyses, the more severely ill subjects were
more likely to commence higher doses. Nevertheless, the
propensity adjustment allowed for evaluation of main-
tenance antidepressant interventions in a nonrandom-
ized study with a more broadly generalizable study sam-
ple than typically seen in RCTs of antidepressants. 
Discussion
The observational study has been described and consid-
ered here as an alternative to the randomized controlled
clinical trial. Although observational studies do not use
randomized treatment assignment, evaluation of inter-
ventions is possible with an appropriate statistical adjust-
ment, but only if the plausibility of statistical assump-
tions is carefully evaluated. This data analytic strategy
was illustrated with evaluations of acute and mainte-
nance antidepressant effectiveness using the NIMH
CDS data for longitudinal, observational analyses of
ordered categorical antidepressant doses. Propensity
score adjusted analyses demonstrated that participants
receiving higher doses during an episode were signifi-
cantly more likely to recover, even though subjects who
received higher doses tended to be more severely ill.
Similarly, participants who received a higher dose of
maintenance antidepressant therapy were significantly
less likely to have a recurrence.
The propensity adjustment provides an opportunity to
examine treatment effects in lieu of randomization.
However, there are critical assumptions of this approach.
First, it is useful to examine the degree to which
between-treatment group balance has been achieved
with the propensity adjustment. Second, it is essential
that the treatment by propensity quintile interaction is
tested before pooling quintile specific results. This is
because an interaction would signify that the treatment
effect varied across quintiles and those quintile-specific
results must be reported separately. Third, Rubin high-
lighted the importance of selection of variables for a
propensity score prior to seeing the outcome data.
21This
parallels the practice of designating a primary outcome
variable and a primary data analytic procedure in an
RCT protocol, prior to collecting data. Finally,
D’Agostino and D’Agostino provide an overview of the
propensity adjustment and emphasize make that it is not
a panacea, particularly with the assumption of no
unmeasured confounding variables.
22 A mis-specified
propensity model will not reduce as much bias as a
model that includes all confounding variables.
Simulation studies have shown this with cross-sectional
23
and longitudinal data.
24 It is therefore important to con-
duct sensitivity analyses.
25
Randomization, in and of itself, does not insulate an
RCT from threats to internal validity. Two common fea-
tures of antidepressant RCT implementation introduce
an observational aspect to group assignment. First, attri-
tion, which is highly prevalent in trials of psychiatric
interventions, introduces bias and reduces statistical
power, feasibility, and generalizability. There are well-
accepted strategies for reducing the impact of attrition.
Adherence to the principle of intention to treat, in which
all randomized subjects are included in the primary
analyses, is critically important.
5,6 (Note that modified
intention to treat seldom includes all randomized sub-
jects and therefore does not reduce as much bias as a
true intention to treat.) Mixed-effects models can include
all data from participants, even those who terminate the
study prematurely.
7,8Analyses of the sensitivity of results
to the assumptions of the analytic model are useful com-
ponents of a data analysis plan. These can include use of
pattern-mixture models
26,27 and the assessment and appli-
cation of predictors of attrition such as the two-item
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flexible-dose study, in which those who fail to respond
to a low dose are then offered a greater dose of the
intervention. Such a design is inappropriate for dose
finding because “self-selection” determines dose.
Fortunately, the use of flexible dose RCTs is more lim-
ited today than two or three decades ago. The problem
of flexible dosing can be obviated by conducting a fixed-
dose study that allows for a brief period of titration.
29
In summary if conditions allow, a RCT is preferable for
intervention evaluation. However, there are clinical con-
texts and patient types that do not lend themselves to
randomized treatment assignment (eg, suicidal patients).
In such a case, an observational study can inform treat-
ment choice if an appropriate adjustment, such as the
propensity score adjustment, is implemented. Regardless
of the design, the generalizability of the results is
restricted to the type of participants included in the
study. ❏
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